tradingview.com
Cure8 news brief
Why This Matters
An investigational immune-targeting drug (SL-325) has moved into Phase 2b testing for Crohn’s disease after tolerable Phase 1 results — this is a development step that could lead to larger efficacy studies. The company’s reported cash runway and leadership hire may affect the pace of development.
Who Should Pay Attention
Patients with Crohn’s disease interested in emerging therapies, clinicians and researchers tracking new immune-pathway drugs, and investors following biotech development timelines.
Study Snapshot
Story typeBusiness news
Evidence typePhase 1 clinical trial
Source depthFull source text
What To Know
Shattuck Labs reported tolerable Phase 1 safety results for its investigational drug SL-325, described in the article as producing durable DR3 blockade, and has started a Phase 2b trial in Crohn's disease with data expected in early 2028.
The company also announced a Q3 2026 financial loss and a cash runway into 2029, and named a new senior clinical development lead. This brief is grounded in the TradingView article text and summary; it does not represent a review of the underlying clinical study report or independent verification of trial data.
It summarizes the company announcement that a Phase 2b Crohn's trial is underway and that Phase 1 results were reported as tolerable. If you follow Crohn's research or are tracking investigational treatments, note the next meaningful milestone will be Phase 2b data expected in early 2028.
Keep In Mind
The article is a company-focused news summary from TradingView; Phase 1 tolerability does not imply effectiveness. The article notes trial start and expected data timing but does not provide detailed trial design or results. Company financials were also reported; these affect development funding but do not speak to clinical benefit.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedNov 10, 2026, 6:39 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Shattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with ...
Early clinical data suggest SL-325 engages its target (TL1A) with a favorable safety signal, and a Phase 2b trial in Crohn’s disease is planned — meaning this could become a new treatment option in the future if later...
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...
Palisade Bio Stock: A Unique MoA Targeting The UC And Crohn's Disease Markets (PALI)
an investigational oral drug (PALI-2108) being developed specifically for UC and Crohn’s disease, reporting favorable Phase 1 safety and early activity and noting upcoming Phase 2 readouts. For people following new...